Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Company Deals Digital

SciClone Pharmaceuticals Partners with JD Healthcare to Pioneer Integrated Immune Health Management Model

Fineline Cube Apr 24, 2026
Company Deals

Mebanks Divests Guangzhou Specialty Pharmacy Subsidiary to DaShenLin for $7.75 Million to Focus on Higher-Margin Health Insurance and Management Businesses

Fineline Cube Apr 23, 2026
Company Deals

AbbVie Announces $1.4 Billion Advanced Manufacturing Campus in North Carolina to Support Immunology, Neuroscience, and Oncology Portfolio

Fineline Cube Apr 23, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC

Fineline Cube Apr 27, 2026
Company Drug

China Medical System’s Comekibart Anti-IL-4Rα Antibody Enters NMPA Review for Seasonal Allergic Rhinitis

Fineline Cube Apr 24, 2026
Company Medical Device

Lifetech’s CS Stent System Wins NMPA Fast‑Track for Aortic Arch Aneurysms, Eliminates Cerebral Ischemia Risk

Fineline Cube Jan 13, 2026

Lifetech Scientific Corporation (HKG: 1302) announced that its Concave Supra (CS) integrated aortic arch triple‑branch reconstruction...

Company Drug

ImmuneOnco’s Timdarpacept Receives NMPA Nod for Atherosclerosis Study, Expanding CD47 Platform

Fineline Cube Jan 13, 2026

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (HKG: 1541) announced that China’s National Medical Products Administration (NMPA) has...

Company Drug

Hengrui’s SHR‑1826 ADC Earns Breakthrough Therapy Designation for c‑Met Overexpressed NSCLC

Fineline Cube Jan 13, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that SHR‑1826, an antibody‑drug conjugate (ADC) targeting...

Company Drug

Hengrui’s HRS-7535 GLP-1R Agonist Cleared for Hypertension with Obesity Study in China

Fineline Cube Jan 13, 2026

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that China’s National Medical Products Administration (NMPA)...

Company Drug

Merck and Abbisko’s Pimicotinib NDA Accepted by FDA for TGCT, Building on China Approval

Fineline Cube Jan 13, 2026

Merck KGaA (ETR: MRK) and Abbisko Therapeutics Co., Ltd. (HKG: 2256) announced that the U.S. FDA...

Company Deals

Hisoar Pharma Invests RMB 150 Million in Wanbangde’s WP205 for ALS, Securing 15 % Global Revenue Share

Fineline Cube Jan 13, 2026

Zhejiang Hisoar Pharmaceutical Co., Ltd. (SHE: 002099) announced a strategic collaboration with Wanbangde New Building...

Company Drug

FDA Approves Zycubo as First Therapy for Pediatric Menkes Disease, Targeting Ultra‑Rare Copper Deficiency Disorder

Fineline Cube Jan 13, 2026

The U.S. Food and Drug Administration (FDA) has approved Zycubo (copper histidinate) injection, the first...

Company

AbbVie Commits $100 Billion US Investment and TrumpRx Expansion for Tariff Relief

Fineline Cube Jan 13, 2026

AbbVie Inc. (NYSE: ABBV) announced a voluntary agreement with the Trump administration to advance drug access...

Company Deals

Bayer AG Acquires Cardiac Amyloidosis Imaging Tracers from Attralus, Including Phase III AT‑01 with FDA Breakthrough Designation

Fineline Cube Jan 13, 2026

Bayer AG (ETR: BAYN) announced an agreement with Attralus, Inc. to acquire two investigational molecular imaging...

Company Drug

BMS’s Camzyos Meets Primary Endpoint in Phase III SCOUT-HCM Study for Adolescent oHCM

Fineline Cube Jan 13, 2026

Bristol-Myers Squibb (NYSE: BMY) announced that the SCOUT‑HCM Phase III study of Camzyos (mavacamten) met its primary...

Policy / Regulatory

NHSA Launches 6th VBP Tender for Medical Consumables in China, Targeting Drug-Coated Balloons

Fineline Cube Jan 13, 2026

China’s National Healthcare Security Administration (NHSA) conducted the 6th volume-based procurement (VBP) tender for high-value...

Company Drug

Summit Therapeutics Submits Ivonescimab BLA to FDA for EGFR‑Mutated NSCLC Post Third‑Gen TKI

Fineline Cube Jan 13, 2026

Summit Therapeutics (NASDAQ: SMMT), the US partner of Akeso Inc. (HKG: 9926), announced the submission of...

Policy / Regulatory

China’s NHSA Launches Pre‑Communication Pilot for Reference Drugs, Targeting Category 1 Innovative Drugs

Fineline Cube Jan 13, 2026

China’s National Healthcare Security Administration (NHSA) released the “Measures for Pre‑Communication on Reference Drugs (draft...

Company Deals

RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6 Billion in Milestones

Fineline Cube Jan 13, 2026

RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) announced an exclusive licensing agreement with AbbVie Inc. (NYSE: ABBV) for...

Company Medical Device

Broncus Medical Secures NMPA Fast‑Track for BroncTarget COPD System, Targeting 9 Million Refractory Patients in China

Fineline Cube Jan 13, 2026

Broncus Medical (HKG: 2216) announced that China’s National Medical Products Administration (NMPA) has granted fast‑track designation...

Company Deals

Boehringer Ingelheim & Jazz Launch Phase I HER2 Breast Cancer Combo with Zongertinib & Zanidatamab

Fineline Cube Jan 13, 2026

Boehringer Ingelheim and Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced a strategic clinical collaboration to evaluate a...

Company Deals Digital

Thermo Fisher Scientific Partners with NVIDIA in $280 Million AI Deal to Automate Laboratory Operations

Fineline Cube Jan 13, 2026

Thermo Fisher Scientific Inc. (NYSE: TMO) announced a strategic collaboration with NVIDIA Corporation (NASDAQ: NVDA) to jointly...

Company Deals

SciNeuro Pharmaceuticals Licenses Alzheimer’s BBB Antibody Platform to Novartis in $1.5 Billion Deal

Fineline Cube Jan 13, 2026

SciNeuro Pharmaceuticals announced a global collaboration with Novartis AG (NYSE: NVS) to advance its next‑generation amyloid...

Company Deals

CARsgen Therapeutics Enters Phase I Collaboration with Dispatch Bio for CT053 CAR‑T in Solid Tumors

Fineline Cube Jan 13, 2026

CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced a clinical collaboration with Dispatch Bio to evaluate DISP‑11,...

Company Deals

Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO‑VC Virtual Cell Models for NSCLC and CRC

Fineline Cube Jan 12, 2026

Noetik, an AI‑native biotech pioneering self‑supervised machine learning in cancer therapeutics, announced a five‑year strategic...

Posts pagination

1 … 48 49 50 … 656

Recent updates

  • NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting
  • Sun Pharma to Acquire Organon for $11.75 Billion, Creating Global Top-25 Pharmaceutical Leader in Branded Generics
  • AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC
  • Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline
  • Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Others

Sun Pharma to Acquire Organon for $11.75 Billion, Creating Global Top-25 Pharmaceutical Leader in Branded Generics

Company Drug

AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC

Company R&D

Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.